Stock INZY INOZYME PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
4.63 USD -3.74% Intraday chart for Inozyme Pharma, Inc. -3.94% +8.69%
May. 30 Wells Fargo Starts Inozyme Pharma With Overweight Rating, $14 Price Target MT
May. 16 Transcript : Inozyme Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Wells Fargo Starts Inozyme Pharma With Overweight Rating, $14 Price Target
MT
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
AQ
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
AQ
Transcript : Inozyme Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
AQ
Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Transcript : Inozyme Pharma, Inc. - Special Call
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
AQ
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency
CI
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
AQ
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency
CI
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
AQ
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INZY Stock
  4. News Inozyme Pharma, Inc.